Hélio Kushima

Hélio Kushima

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
FBFlavia Bonamin
Flavia Bonamin
TMThiago M. Moraes
Thiago M. Moraes
RSRaquel C. dos Santos
Raquel C. dos Santos
HKHélio Kushima
Hélio Kushima
FFFelipe M. Faria
Felipe M. Faria
CHClelia Hiruma-Lima
Clelia Hiruma-Lima

Verified
Journal Article
Open access
PDF file
MSMaria Luiza Santos da Silva
Maria Luiza Santos da Silva
CTCristal de Jesus Toghi
Cristal de Jesus Toghi
ASAugusto Antunes Oliveira Fraga da Silva
Augusto Antunes Oliveira Fraga da Silva
HSHellen Cristiny Cavalcanti de Souza
Hellen Cristiny Cavalcanti de Souza
BJBeatriz Dragoneti Jorge
Beatriz Dragoneti Jorge
CDCarlos A Dias-Junior
Carlos A Dias-Junior
Preeclampsia is a hypertensive disorder of pregnancy associated with elevated levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and reduced nitric oxide (NO) bioavailability. Esomeprazole (ESO), a proton pump inhibitor (PPI) considered safe during pregnancy, has been proposed to reduce sFlt-1 levels in vitro. This study evaluated the effects of ESO in pregnant rats subjected to reduced uterine perfusion pressure (RUPP), a well-established model of preeclampsia. Pregnant rats received saline (Preg) or ESO (Preg+ESO), while RUPP-operated rats received saline (RUPP) or ESO (RUPP+ESO). At gestational day 21, maternal blood pressure was elevated in the Preg+ESO, RUPP, and RUPP+ESO groups compared with Preg, and ESO did not attenuate RUPP-induced hypertension. Fetal and placental weights were reduced in the RUPP group, whereas ESO increased placental weight in Preg+ESO and RUPP+ESO groups. Gastric pH was elevated by ESO, confirming reduced gastric acidity. Plasma sFlt-1 levels were increased in RUPP and significantly reduced by ESO in RUPP+ESO rats. NO metabolites (NOx) were decreased in RUPP but were unaffected by treatment. Endothelium-dependent relaxation was impaired in the RUPP and RUPP+ESO groups. In conclusion, ESO did not prevent hypertension or endothelial dysfunction, but reduced circulating sFlt-1, suggesting a partial modulatory effect on angiogenic imbalance in experimental preeclampsia.

10 September 2025 in bioRxiv
Verified
Preprint
Open access
NMNoemia A. P. Mariani
Noemia A. P. Mariani
NSNatália C. M. Santos
Natália C. M. Santos
JAJuliana J. Andrade
Juliana J. Andrade
AAAlexandre D. Andrade
Alexandre D. Andrade
BRBeatriz Rezende
Beatriz Rezende
ESErick J.R. Silva
Erick J.R. Silva
Seminal plasma is essential for sperm survival and function after ejaculation. Semenogelin-1 (SEMG1), the predominant seminal plasma protein, transiently suppresses sperm motility and hyperactivation after ejaculation through epididymal protease inhibitor (EPPIN) binding. However, the molecular mechanism underlying SEMG1-mediated inhibition of hyperactivation remains unclear. Here, we tested the hypothesis that SEMG1 inhibits CatSper, a sperm-specific calcium channel crucial for hyperactivation. Full-length recombinant mouse SEMG1 (mSEMG1; Q32-G375) inhibited both progressive motility and hyperactivation; the latter was not recovered with NH 4 Cl-induced alkalinization, indicating an effect downstream of capacitation-associated intracellular alkalinization. Electrophysiological recordings revealed that mSEMG1 reduced CatSper currents at physiologically relevant concentrations. Truncated mSEMG1 fragments mSEMG1 Q32-V118 and mSEMG1 R98-G375 , but not mSEMG1 Y221-G375 , inhibited sperm hyperactivation and CatSper currents to a similar extent as full-length mSEMG1. Notably, only mSEMG1 R98-G375 retained full EPPIN-binding capacity. Together, our findings identify two functional domains within mSEMG1 (Q32-V118 and R98-S220) that inhibit sperm hyperactivation by suppressing CatSper activity and differ in their EPPIN-binding capacities. These functional domains represent promising prototypes for the design of spermiostatic molecules, offering additional avenues for non-hormonal male contraception. Summary statement: We report a novel mechanism by which SEMG1, a major seminal plasma protein, modulates sperm hyperactivation by inhibiting a key calcium channel, offering new insights into sperm function and non-hormonal male contraception.